AbbVie

IThe business

AbbVie makes and sells prescription medicines, mostly injected or swallowed drugs for autoimmune disease, plus migraine, Parkinson’s and psychiatric drugs, blood cancer drugs and Botox. It is based in North Chicago, Illinois, has about 57,000 employees and sells in more than 180 countries.⁸ In the first nine months of 2026 three quarters of revenue came from the United States, and three wholesalers account for 82% of what customers owe the company.³⁶ The customers who matter most are the insurers and pharmacy benefit managers that decide which drug sits on a formulary, and the government.

The model is simple to say. A drug costs a great deal to find and prove. Once it works and is protected, each extra sale is nearly all profit: the adjusted gross margin was 85.1% in the third quarter.³ The company then pays out most of that to shareholders and uses the rest to buy the next drug. AbbVie became independent of Abbott on 1 January 2013 around one product, Humira, which was about 65% of revenue in 2017.¹⁰ The story since is how it got out from under it.

Humira, and what replaced it

Humira reached $21.2B in 2022. Its US compound patent expired in December 2016, but copies did not reach the United States until 2023, when the 10-K says direct biosimilar competition began.¹⁰⁷ Revenue then fell to $14.4B, $9.0B and $4.5B, a fall of 79% in three years C (calculated).⁵ In the first nine months of 2026 it made $2.1B, down another 35%.³ A reader who stopped there would call it a cliff.

It was not, because of what had been built beside it. Skyrizi, an injected drug for psoriasis and bowel disease, went from $1.6B in 2020 to $17.6B in 2025. Rinvoq, a daily pill for arthritis, eczema and bowel disease, went from $0.7B to $8.3B.⁷⁵ In 2025 the two together were $25.9B, already above Humira’s best year C (calculated). For 2026 call summaries give the company’s forecast as $21.8B and $10.3B, together $32.1B, or 47% of expected revenue C (calculated).⁴² Total revenue was $58.1B in 2022 and is guided to about $67.8B for 2026 on the call (second-hand), so AbbVie grew while losing its largest product.⁷²

What it sells

This is the nine-month 2026 list, in order of size. Immunology is half of the company, and two drugs are most of immunology.

Neuroscience, aesthetics and the rest

Neuroscience is the second leg. It made $9.5B in nine months, up 21.6%, and the company forecasts about $13B for the year.³⁴ Vraylar is forecast at $4.2B, the two migraine pills at $3.1B and Botox Therapeutic at $4.2B.⁴ In September the FDA approved Juvmo (tavapadon), a Parkinson’s tablet that came with the 2024 purchase of Cerevel, and management says its Parkinson’s drugs together could pass $5B at peak, though for Juvmo broad Medicare cover is not expected until 2028.³⁴

Aesthetics is the weak leg. Revenue was $5.3B in 2022 and $4.9B in 2025, a fall of 9%, because Juvederm fillers lost ground C (calculated).⁷⁵ The 2026 outlook is $5B, and Botox Cosmetic is forecast at $2.8B.² The business sells to patients who pay out of pocket, so it moves with consumer spending and not with insurance.

Oncology made $5.0B in nine months, flat, because Imbruvica fell 27% as Medicare prices began in 2026 while Venclexta, Elahere and Epkinly grew.³ In October AbbVie filed for approval of etentamig, a myeloma treatment, and it holds breakthrough status on a cancer drug it calls Temab-A.³ None of this yet replaces what Imbruvica is losing.

Where the margin goes

The adjusted operating margin was 48.7% in the third quarter. GAAP was 36.0%. The 12.7 point gap is $1.7B of amortization of purchased drugs and $0.5B of deal and other costs. Below operating profit sits a further $0.8B charge because the Skyrizi obligation grew.³ I use the adjusted figure for the business and the GAAP figure to see what deals cost, and Section V takes the gap apart. Adjusted costs were 15% of revenue for goods sold, 21% for selling and administration and 14% for research.³

Debt is large. Gross debt was $80.9B on 30 September, against $67.5B at the end of 2025, after $18.0B of new bonds in 2026, the year it paid $10.6B for Apogee, a developer of drugs for skin and lung inflammation.⁶ The company says it is on track to reach a net leverage ratio of two times over the next two to three years, which I read as net debt against earnings before interest, tax and depreciation.² I come back to that in Section V.

IIThe moat

What protects AbbVie’s profit? I look at it drug by drug, because the company is not one business. Each protection has a date, and the dates are what matter to an owner.

What protects it, source by source

Patents. The US composition-of-matter patents on both Skyrizi and Rinvoq are expected to end in 2033.⁵ For Rinvoq, AbbVie settled with every generic maker that had filed in September 2025, and the 10-K says no generic tablet is expected to enter the US before April 2037, if a six-month pediatric extension is granted.⁵ That is four years past the compound patent, and it is the single most valuable fact in the filings. For Skyrizi I found no settled date. The 10-K says only that the composition patent ends in 2033. Humira is the warning: its compound patent ended in December 2016 and meaningful US biosimilar sales began in 2023.¹⁰⁷ A biologic is hard to copy, and AbbVie knows how to build a wall of later patents. I can’t tell how that goes for Skyrizi.

Evidence. The strongest protection after a patent is evidence that doctors trust. In October 2025 AbbVie reported that in a head-to-head study Rinvoq beat Humira in patients who had failed one other TNF blocker.⁵ In the 2026 quarters it reported more bowel disease data for both drugs, and a US approval in October for Skyrizi as an under-the-skin start in Crohn’s disease.³ Those studies make it harder for a plan to swap a patient to something cheaper.

Habit and contracts. A gastroenterologist who has put patients on Skyrizi is slow to switch, and plans pay rebates for formulary position. That is a real barrier, but I can’t measure it from the filings and I treat it as thin beside the patent.

Evidence it is widening

Skyrizi grew 25.6% in nine months from a base of $12.6B and Rinvoq 23.9% from $5.9B C (calculated).³ New uses keep arriving: Rinvoq in vitiligo and alopecia in Europe, a pediatric arthritis approval, and two more filings in the US.⁶ The company says the two new Rinvoq uses together could add nearly $2B of peak sales.² Gross margin of 85% and an adjusted operating margin near 49% suggest that nobody has yet forced the company to cut price in its core.³

Evidence it is narrowing

The protection has a date, and three things on the page show the edges. First, Humira. The same company, same sales force and same doctors saw 79% of the revenue go once biosimilars were allowed to compete.⁷⁵ Second, government prices. Imbruvica, picked in 2023, fell 27% in nine months as Medicare prices began; Vraylar and Linzess follow in 2027 and Botox was picked for 2028.³⁵ Third, the new drugs are both approved in 2019, Skyrizi in April and Rinvoq in August.¹¹ The 10-K says Medicare prices can apply to a pill more than nine years after approval and to a biologic more than 13, and selection comes about two years ahead.⁵ By that clock Rinvoq could be chosen in the list due in February 2027 for prices in 2029, and Skyrizi by February 2031 for prices in 2033 E (estimate). That is my reading of the dates, not the company’s. Whether each is chosen depends on how much Medicare spends on it, which I can’t see.

The company has some cover. In January 2026 it signed a voluntary agreement with the government: low Medicaid prices, direct-to-patient sales and a pledge of $100B of US research and investment over ten years, in return for three years without tariffs or new price mandates.⁶ That does not switch off the statute. I read it as protection against new rules, not against the Medicare price-setting already written into law.

Verdict. The protection is strong and short. Strong, because Skyrizi and Rinvoq hold up against every current alternative I can see in the filings. Short, because the best-case dates are 2033 and 2037 and the likely date for a government price cut is earlier.

IIIThe competitive advantage

Is AbbVie better than its peers at turning science into cash? Strong protection is one thing, and a company that uses it well is another. I compare AbbVie with the two other drug makers I have written up, where the page figures are mine and the numbers come from those pages.

Where AbbVie wins

It wins on diversification. Lilly earns 64% of revenue from one molecule and Novo 74%; AbbVie’s largest drug is 32% and its second, Rinvoq, is 15%.¹³¹⁴⁴² Three or four large products fail in different years. It also wins on how long it has already been through a cliff. The company has done this once, at a loss of $16.7B of Humira revenue, and grew through it.⁷⁵

It wins on profit per dollar of sales. The adjusted operating margin of 48.7% in the third quarter is high even for a drug company.³ And it wins on distribution: the same sales force and payer contracts that sold Humira now sell Skyrizi and Rinvoq into the same clinics. A newcomer with a good drug would have to build that.

Where it loses

It loses on growth that is still ahead. Lilly is growing four times as fast and has a patent to 2036; AbbVie’s two drugs are older and their dates are closer.¹³ It loses on what it owes: $80.9B of debt, $27.3B of Skyrizi payments and an equity deficit of $4.5B, compared with the cash-rich balance sheets of the diabetes and obesity leaders.⁶ And it loses on dependence on buying. Lilly and Novo built their leading drugs in their own laboratories. A large share of AbbVie’s new pipeline, Cerevel, ImmunoGen, Stemcentrx, Capstan and Apogee among them, was bought, and not all of what it bought has worked.⁵¹²⁶

Who can compete with AbbVie in immunology? The 10-K lists no single rival as the threat; it says only that the market is highly competitive and that biosimilars and orally administered drugs press on Humira.⁵ I don’t have a filing-based view of the other IL-23 drugs or of the oral drugs now in trials, and so I can’t put a number on their effect. That is part of why the bear case is as low as it is.

IVManagement

How he is really paid

Robert Michael has been chief executive since July 2024 and chairman since July 2025. Richard Gonzalez, who ran the company from its start in 2013, stayed as executive chairman until 1 July 2025.⁸ Michael’s total pay for 2025 was $32.5M, up from $18.5M in 2024 and $14.4M in 2023. The parts were a $1.7M salary, $13.3M of stock awards, $3.2M of options, a $5.2M cash bonus, an $8.6M rise in the value of his pension and $0.5M of other pay. His pay was 192 times the median employee’s $169,019.⁸

What does that pay him to do? The annual bonus rests on four numbers: platform revenue, which is sales without Humira; adjusted pre-tax income; adjusted return on assets; and adjusted operating margin. For 2025 all four beat target, by 3% to 5%.⁸ The long-term award is 40% performance shares on adjusted EPS, 40% share units on return on invested capital against other drug makers, and 20% options. In 2025 adjusted EPS of $10.00 came in over the $9.66 maximum and paid 200%, and the return on capital rank, at the 95th percentile, also paid 200%.⁸

Two points matter here. First, the measures are all adjusted. Adjusted earnings leave out the amortization of drugs the company bought, and a charge such as the $4.7B change in the Skyrizi obligation in nine months.³⁶ So buying growth costs the pay measures less than it costs the cash. Second, the proxy says the goals are set without charges for acquired research, and that the 2025 targets were then adjusted for the charge that came, so buying pipeline does not lower pay either.⁸ That is neutral by design. It does not discourage the deals that are the largest use of cash after the dividend.

Who runs it

Michael is also chairman, so the same person leads the company and the board. Roxanne Austin has been lead independent director since 2024, the first new one since 2013, and twelve of thirteen directors are independent.⁸ At the May 2026 meeting a proposal to require an independent chair got 39.6% of the votes cast, and pay was approved by 94.7% C (calculated).¹⁵

Their own money

Michael held 178,737 shares in March 2026, about $53M at $294.83, plus 395,588 options he can use within 60 days.⁸¹ The company requires six times salary, which is $10.2M, so he is far above the floor, and executives may not sell stock until they meet it.⁸ All directors and executive officers together held 1,020,964 shares, about 0.06% of the company C (calculated).⁸ That is meaningful money for each person and a small share of the whole. The largest holder is Vanguard at 10.0%.⁸ I did not check the Form 4 record for purchases or sales.

Capital over a full cycle

The test of an allocator is what the cash did. From 2016 to 2025 AbbVie’s operating cash flow was $170B. It paid $80B in dividends, 47% of that cash, spent $74B on deals, 44%, bought back $28B of stock and spent $7.4B on plants and equipment C (calculated).⁵⁷¹¹¹² The sum is $190B, about $20B more than the cash the business made, and the rest came from new debt and from stock issued for deals.

The dividend was the steady part. It rose from $2.35 a share in 2016 to $6.65 in 2025, 12.3% a year, and the board has now voted $7.28 a year from February 2027.⁵¹²³ The share count did not fall. Diluted shares were 1,631M in 2016 and 1,773M in 2025, because the Stemcentrx and Allergan deals were part paid in stock C (calculated).¹²⁵ Buybacks mostly offset that dilution. The biggest year, 2018, spent $12.0B when the average close was about $97; the stock fell 49% from its January 2018 high of $123.21 to $62.98 in August 2019.¹²¹ In 2026 so far the company has bought 5M shares for $1.1B, about $220 each.⁶

The deal record

Deals are where an owner needs to look hardest, because they decide what the next ten years of earnings are. Here is the record, with the outcome I can verify.

The pattern is two clear wins, Skyrizi, whose rights AbbVie acquired from Boehringer Ingelheim in 2016, and Allergan, which brought in a $13B neuroscience business.¹⁰⁴ It is also several write-downs, and large unfinished bets. I give management credit for the first and for the leverage it has held since Allergan, while debt stays near $65B to $81B. The write-downs say that buying pipeline is not safe. They are why I charge a deal budget to every year of the valuation.

VFinancials

Reported earnings and cash differ here more than at most large companies. I read three versions: the GAAP figure, the company’s adjusted figure, and what is left for an owner.

Margins

GAAP operating margin was 36.4% in 2016, 16.2% in 2024 and 24.6% in 2025 C (calculated).¹²⁵ The dips are write-downs and pipeline charges, not weak sales: 2018 holds the Stemcentrx write-down, 2023 and 2024 hold $4.2B and $4.5B of impairments, and 2025 holds $5.0B of acquired research.¹²⁵ The adjusted operating margin was 48.7% in the third quarter of 2026 and the company expects about 46.7% for the year, after a 1.8 point hit from acquired research.³² The gap is mostly amortization of purchased drugs, which was $7.4B in 2025.⁵ It is a real cost of the deals even though it is not cash.

What an owner can really take out

Start from operating cash flow, take off capital spending and stock pay, and you have what the business made for its owners before deals. Then take off cash paid for acquisitions and pipeline deals, which AbbVie books in investing and so keeps out of operating cash flow.⁵ The table puts three periods side by side.

In 2025 the company reported $4.2B of earnings, adjusted its way to $17.7B, and left an owner $11.4B after deals, just under the $11.7B it paid in dividends. In the twelve months to September the figure is $4.8B, because Apogee cost $10.6B. Dividends were $12.1B C (calculated).⁵⁶ That is the central fact of this page. AbbVie pays out about all of what it makes after standing still, and when it makes a large purchase the dividend is, in effect, funded with debt.

What it takes to stand still

Standing still means keeping revenue where it is while patents end. The business pays for part of that inside the margin: research was 13.9% of revenue in the third quarter, about $9B a year.³ The rest it buys, as acquired research, licences and deals. That cost is not in the margin or in operating cash, and so it is easy to forget.

How much is enough? I can’t know, and the record is wide. Deals averaged $7.4B a year over ten years, $3.6B without Allergan, and $9.1B a year from 2023 to 2025 with the two large 2024 purchases.⁵¹¹ In 2026 the company says it expects more small and mid-sized deals and not another Allergan.² I charge 7.5% of revenue every year in the base, which is $5.5B in 2027, and 8.5% in the bear and 6.5% in the bull E (estimate). A range from about $4B to $7B a year moves the base value by roughly $14 a share for each 2.5 points of revenue E (estimate).

On those numbers, 2027 owner cash after interest and Skyrizi payments is about $17B in my base, against a dividend of $12.9B once the 5.2% rise is in E (estimate). So the dividend is covered about 1.3 times, after a stand-still deal budget. That is enough to hold it, and not enough to pay down much debt without help from growth.

The balance sheet

On 30 September AbbVie had $80.9B of debt and $10.8B of cash, so net debt of $70.1B C (calculated).⁶ Beside it is a second debt-like item, the Skyrizi obligation, at $27.3B of fair value, up from $25.4B at the end of 2025 after $4.7B of growth in nine months and $2.8B of payments.⁶ The 10-Q assumes payments run to 2037 for Skyrizi at a 5.4% discount rate, and that the payment is 93% likely on average.⁶ It is a cost of Skyrizi’s success: it grows when Skyrizi sells more, and it shrinks if Skyrizi disappoints.

Together that is $97.4B of claims ahead of the shares, $55 a share C (calculated). Net debt would be 1.9 times my 2027 base earnings before interest, tax and depreciation if it did not change, near the company’s target of two times E (estimate).² So the target is likely reached through growth and not repayment, provided there is no large new deal. Net interest was $2.0B in nine months.³ Goodwill and purchased intangible assets are $94.5B of $147.7B in assets, so another large write-down of an acquired drug is possible. Equity is negative, at −$4.5B.⁶

Tax

The GAAP tax rate was 36% in 2025, −15% in 2024 and 22% in 2023, because write-downs and deal charges are taxed unevenly.⁵ The adjusted rate was 18.0% in 2025 and 13.6% in the third quarter of 2026.¹⁷³ Cash tax ran above the book charge: the cash flow statement shows $2.0B of tax outflow beyond expense in nine months of 2026 and $0.8B in 2025.⁶⁵ I use 16% on adjusted operating income, below 2025 and above this year’s quarter, and I put 1.5% of revenue of other cash costs on top for integration, litigation and the cash-settled awards that come with deals E (estimate). These are judgements and I flag the range at 14% to 20% in Section VI.

The shares

The price has risen 5.3 times in ten years and about 49% since April 2026 C (calculated).¹ Revenue grew 10.1% a year over the same nine years, but much of that was Allergan C (calculated).¹²⁵ The close of $294.83 is within 0.02% of the highest close in the ten-year record, $294.89 on 30 October.¹ At that level the dividend yield is 2.35% on the current $6.92 and 2.47% on the $7.28 from February C (calculated).³

AbbVie, ten years

VIValuation

First, how this goes badly wrong

Before the numbers, I asked what would most likely ruin the business or the investment, and worked back. Three things could, and none needs a surprise.

• The two drugs end sooner, or cheaper, than their patents say. Skyrizi and Rinvoq are 47% of expected revenue.⁴² Their US patents end in 2033 and Medicare can set prices before then.⁵ Humira lost 79% of its revenue in three years once copies arrived.⁷⁵ If Skyrizi did the same after 2033, and Medicare cut Rinvoq earlier, nothing else in the company could fill the hole in time. This is my bear case, worth $44.
• Money goes into pipeline that does not pay. In the last twelve months AbbVie spent $13.1B on deals, while write-downs of bought drugs were $9.6B over 2023 to 2025 C (calculated).⁵⁶ With $97B of net debt and Skyrizi obligations ahead of the shares, a run of bad deals and a sales shortfall at once would force a choice between the dividend and more debt. Each 10% fall in enterprise value is a 12% fall in the shares C (calculated).
• The owner pays too much. This needs nothing to go wrong at AbbVie. The business can do everything I expect and the shares can still return little, because the price already assumes it. On my numbers this is the most likely of the three.

The first two sit inside my bear case. The third is what the rest of this section measures.

What the price implies

At $294.83 AbbVie is worth $522B on 1,772M diluted shares, the 1,768M outstanding on 30 September plus 4M of dilution C (calculated).¹⁶³ Add $70.1B of net debt and the $27.3B Skyrizi obligation and the whole business is priced at $620B, or 9.1 times 2026 revenue C (calculated).⁶ The price is 21.1 times the midpoint of 2026 adjusted EPS guidance, $13.97, 18.4 times the Nasdaq consensus of $16.03 for 2027 and 16.4 times $18.01 for 2028 C (calculated).³¹⁸ The consensus for 2029 is $18.13, which is 0.7% growth, so the Street itself sees a pause then.¹⁸ For comparison, the Lilly page shows Lilly at 30.0 times its 2027 consensus, Johnson & Johnson at 23.7 and Merck at 16.1.¹³

The owner yield is lower than the headline. On the twelve months to September, owner cash after stock pay was $17.9B, or 3.4% of the market value. Take off a stand-still deal budget of about $5.5B and it is $12.4B, or 2.4% E (estimate). The ten-year Treasury yields 4.90%.¹⁹ In my 2027 base, owner cash after interest and Skyrizi payments is $16.6B, a yield of 3.2% E (estimate).

What does the price pay for? Holding the margin flat at 49.5%, close to the 49.9% of the third quarter before acquired research, the price needs revenue to grow 10.5% a year for ten years C (calculated). That takes revenue from $67.8B to $184B by 2036, more than two and a half times. The nine-month growth of 2026 was 10.9%, and the nine years from 2016 to 2025 grew 10.1% a year, but that included Allergan C (calculated).³⁵¹² The company itself has spoken of high single digits through 2029.⁹ Nothing in the filings points to the second five years of growth the price asks for, with patents ending in the middle of them.

What I can’t judge

Four inputs drive this value, and none of them can be known today. I show them as ranges for that reason, and I do not trust one number.

When Skyrizi biosimilars arrive. The patent ends in 2033 and I found no settlement date. Humira’s compound patent ended in December 2016 and copies reached the United States in 2023, which is more than six years.¹⁰⁷ My base starts the fall in 2034 and takes most of it in 2035 and 2036. How hard Medicare cuts. I don’t know whether either drug will be picked, how many Medicare patients each has, or the size of the cut, and the January 2026 agreement with the government covers new price mandates and not this statute.⁶ What the recent deals earn. Apogee, Capstan, Cerevel and ImmunoGen are early, and I can’t value them. The cash behind adjusted earnings. Tax, integration and legal costs have run above the adjusted figures, and I estimate the gap.

The discount rate

I use 9.0%, the same hurdle as on my Eli Lilly and Novo Nordisk pages. The ten-year Treasury yields 4.90% and Damodaran’s implied equity risk premium was 4.20% on 1 October.¹⁹²⁰ AbbVie’s month-end beta against the S&P 500 ETF is 0.48 over ten years, 0.18 over five and −0.03 over three, which gives 6.9%, 5.7% and 4.8% C (calculated).¹²¹ Those numbers describe a stock that happened to move little with the market. They say nothing about a company where two drugs make 47% of revenue and the dates are known. So I don’t use them. The sensitivity table shows what other rates do.

Three cases

The model is built line by line. I take revenue as four lines: Skyrizi, Rinvoq, Humira and everything else. I set adjusted operating margin before acquired research, tax it at 16%, and take off net capital spending, working capital at 10% of added revenue, other cash costs at 1.5% of revenue, and deals at 7.5% of revenue. Stock pay is already in the margin and I do not add it back. What is left is owner cash before interest. I then take off net debt and the Skyrizi obligation, as claims ahead of the shares.

Two choices matter. I treat the $27.3B Skyrizi obligation as debt and do not count the payments in the annual cash, so there is no double count. And I charge deals every year, because a company that loses a patent every few years has to buy or build the next one. If I left deals out, the base would be $155, and I think that would be wrong.

My base 2027 adjusted operating income is $36.3B. After about $2.8B of interest and a 15% tax rate, that is about $16.08 a share, near the consensus $16.03 for 2027. My 2028 is $17.44 against $18.01 E (estimate).¹⁸ So I am close to the Street on the near year and lower on the next, and the difference grows as patents begin to matter.

Bear. Medicare picks Rinvoq for 2029 prices and cuts it hard, Skyrizi biosimilars reach the market in 2034 and take a fifth to a quarter of Skyrizi sales a year from then, the rest of the portfolio shrinks as Vraylar and Imbruvica fall, and deals take 8.5% of revenue to hold the line. Revenue falls to $53B by 2036. Base. Skyrizi grows to $35B in 2032, Rinvoq to $14B, Medicare takes a share in 2029 and 2033, and copies begin to bite in 2034 to 2036. New drugs hold the rest of the portfolio to 3% growth. Bull. No Medicare cut hurts Rinvoq, Skyrizi reaches $41B and holds until 2035, and Parkinson’s, obesity and cancer launches carry the rest to 4% a year.

Where is the cliff in the base? It is not one year. Skyrizi and Rinvoq together peak at $49B in 2032 and fall to $33B in 2036, and the rest of the portfolio grows from $33B to $42B only if the new launches work E (estimate). The year-ten cash flow is cut by 12% before the long-run value, for Rinvoq’s own generic date in 2037, and then grows at 3%.

The price sits 161% above my base and 61% above my bull. That is the plain result. Why might the market be right? Because it can see what I can: two drugs growing 24% to 26%, a 10.9% growth rate, a company that has already rebuilt itself once, a court that set aside the first Botox selection on 29 October, and an adjusted margin near 50%.³⁶ It may be paying for what I leave out, such as the Parkinson’s launch, new uses of Rinvoq, a possible obesity drug and a Skyrizi that lasts beyond 2035. If those are worth more than I can price, my values are too low. The $44 bear is a fair picture of the world in which they are not.

The same dollar, elsewhere

The ten-year Treasury pays 4.90%.¹⁹ Against that, my base returns 5.6% a year from this price, my bear 4.2% and my bull 7.0% E (estimate). The nearest comparison on this site is Eli Lilly, where my base equals the price only at 6.3%, and Novo Nordisk, at 7.3%.¹³¹⁴ So AbbVie’s price is further above my base than either, though AbbVie has the least concentrated business. That is not a contradiction. Lilly’s price has more room to grow into, and Novo’s has already fallen. AbbVie’s has risen 49% since April on results that match the plan.¹ On the same method, Novo is the closest of the three to its base. Quality and price are two separate questions, and here the business is good and the price is high.

From my value to the price, one change at a time

How the odds shrink

If the case needs many things to go right at once, multiply them. The price needs, roughly, all of these. Skyrizi and Rinvoq keep growing after 2033: 45%. Medicare cuts stay modest: 55%. New drugs add $20B or more to the rest by 2035: 40%. Deals stay near a stand-still level and earn their cost: 60%. Those are my guesses. Multiplied they give 6% E (estimate). They overlap, so perhaps 10% to 15% in practice. A price that needs something like a one-in-ten outcome leaves no room for error, even for an excellent business.

The margin of safety

My margin-of-safety price is $79, the base value less 30%, a cushion for the four things I cannot judge. The price is 3.7 times that. At $79 my base would return 10.8% a year and the dividend yield, at $7.28, would be 9.2% E (estimate). The bear case is $44. I don’t expect the price to go there. The point is what an owner would need to see before the numbers favour them, and it is not close.

VIIThe case for the price

What most people miss

Three facts cut in AbbVie’s favour and get little attention. First, the replacement is not a forecast. Skyrizi and Rinvoq made $25.9B in 2025, above Humira’s best year of $21.2B, and the company now guides them to $32.1B for 2026.⁷⁵⁴ Second, the Skyrizi obligation is a partial hedge. The $27.3B liability rose by $4.7B in nine months because Skyrizi sold more, and it would shrink if Skyrizi sold less.⁶ Third, Rinvoq’s protection is longer than its patent: with every generic filer settled, no generic tablet is expected before April 2037, four years after the 2033 compound patent.⁵

The bull case

In plain words: AbbVie did the hard thing, losing its biggest drug and growing anyway, and the next set of drugs is still early in its life. The company’s chairman and chief executive, Robert Michael, said on 30 October that the quarter showed “solid execution across our diverse portfolio,” that the company had “enhanced our long-term growth potential,” and raised guidance and the dividend.³ In January 2025 the company said it expected high single-digit compound annual revenue growth through 2029, off a 2024 base of $56.3B, which is a 9.7% annual rate to the 2026 guide of $67.8B C (calculated).⁹² The Nasdaq consensus has earnings of $16.03 in 2027 and $18.01 in 2028, and at 16.4 times 2028 that is lower than Lilly at 25.4 times.¹⁸¹³ On that view the shares are a fair price for a compounder with a 2.5% dividend and a growing pipeline: tavapadon approved, etentamig filed, an obesity candidate in early trials, and two new Rinvoq uses.³²

I found no named investor or analyst statement on AbbVie that I could open and check, so I have not attributed the bull case to anyone beyond the company itself and the published consensus. The Nasdaq page for the stock shows a one-year target of $300, with no firm named.¹⁸

Against reality

Much of the case is already in the price. My bull has revenue growing 4.1% a year for ten years, to $101B, with an adjusted margin near 50%, and it is worth $183 E (estimate). The price asks for 10.5% a year, which is revenue of $184B in 2036, 2.7 times this year’s C (calculated). So if AbbVie keeps growing near its nine-month 10.9% for a decade, and the dates on Skyrizi and Rinvoq do not bite, the price is possible. That is what the case has to show, and my bull peaks at $58B for the two drugs together.

Where the argument is weakest is time. Skyrizi’s and Rinvoq’s US patents give the market only until 2033 and 2037, and Medicare can reach both earlier.⁵ The Street’s own 2029 number is almost flat on 2028.¹⁸ And the company’s history of buying growth includes $9.6B of write-downs in three years, and a $13.1B purchase in the last twelve months.⁵⁶

Multiplied out in Section VI, the four things the price needs come to about 6% before overlap and perhaps 10% to 15% after it E (estimate). My base needs less and is not likely either, but its odds are better.

What a 10x would take. Ten times $294.83 is $2,948, about $5.2T of market value on today’s shares C (calculated). At 20 times earnings that needs about $261B of net income, ten and a half times this year’s adjusted figure of about $25B. At the same adjusted net margin of 36.5% it needs about $715B of revenue, ten and a half times 2026. To get there by 2036 revenue would have to grow 27% a year for ten years, against the 10% AbbVie managed over nine years with Allergan in it. The Lilly page puts Lilly, the most valuable drug company on this site, at $1.27T.¹³ A tenfold gain for AbbVie would make it more than four times that. The one case I can show is NVIDIA, from about $0.51T on 2 July 2021 to about $5.8T on 6 October 2026, on about 25B shares and 24.1B, during an AI chip boom C (calculated).²²²³ I know of no drug maker that has done anything like it. For AbbVie, tenfold is close to impossible, and I would not build a case on it.

Where I come down

The replacement of Humira moved me: it is done, and it is bigger than I expected, which is why my base has revenue rising 8% in 2027. Rinvoq’s April 2037 date also moved me. The price did not: it needs 10.5% growth for ten years, and nothing I can open says that is likely. What would raise my values most is a settled Skyrizi biosimilar date after 2035, no Medicare selection of Rinvoq in the next two lists, and two years of deals under $5B.

VIIIRisks, and what would change my view

The three ways this goes badly wrong are at the start of Valuation. These are the rest.

• Medicare price-setting. Imbruvica has been under it since 2026, Vraylar and Linzess follow in 2027, and Botox was picked for 2028.⁵ A court set the Botox selection aside on 29 October 2026, but the government can appeal, and AbbVie itself says more of its products could be picked, which could speed erosion ahead of patent dates.⁶⁵
• Voluntary agreement. In January 2026 AbbVie agreed low Medicaid prices, direct-to-patient sales and $100B of US investment over ten years in return for three years’ relief from tariffs and new price mandates.⁶ After the three years the protection ends, and I cannot say what replaces it.
• Debt and the Skyrizi obligation. $8.7B of debt falls due within a year, and the company is carrying $80.9B in all.⁶ The Skyrizi obligation is a long-dated claim that the company carries at $27.3B of fair value, and I use that figure as it stands. The rate used rose from 4.0% to 5.4% in a year.⁶ A higher rate lowers the liability and a higher Skyrizi forecast raises it.
• Litigation. The company carries a reserve of about $1.3B for litigation.⁶ The cases include antitrust suits over a 2005 Niaspan settlement, about 195 opioid suits against Allergan, about 1,470 Biocell breast implant suits in one US court, and a 2025 class action that says Humira rebates held back biosimilars.⁶⁵ I can’t size them beyond the reserve and I add nothing to it.
• Customer concentration. Three US wholesalers hold 82% of the receivables.⁶
• Consumer spending. Aesthetics is paid for by patients out of pocket, and it fell 9% from 2022 to 2025.⁷⁵
• Obesity. AbbVie has a long-acting amylin candidate with an 11- to 12-day half-life in a Phase 1 study. Lilly and Novo are far ahead, and success here would be a bonus; I do not value it.³
• Accounting gap. The adjusted EPS guide of about $13.97 for this year compares with GAAP EPS of $4.79 in nine months. The gap is mostly purchased-drug amortization and the Skyrizi obligation, but a reader who uses only adjusted numbers sees more earnings than the business pays out.³